Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer by Mythili Shastry, Saya Jacob, Hope S. Rugo, Erika Hamilton

Get full text

Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging... by Maxwell R. Lloyd, Seth A. Wander, Erika Hamilton, Pedram Razavi, Aditya Bardia

Get full text

317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors by Leisha Emens, Naomi Hunder, Samuel Klempner, Erika Hamilton, Muralidhar Beeram, Valerie Odegard, Sue Hamke

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer by Mark Pegram, Richard Pietras, Chau T. Dang, Rashmi Murthy, Thomas Bachelot, Wolfgang Janni, Priyanka Sharma, Erika Hamilton, Cristina Saura

Get full text

A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States by Jacqueline Brown, Savannah Scardo, Michael Method, Dan Schlauch, Amanda Misch, Shaita Picard, Erika Hamilton, Suzanne Jones, Howard Burris, David Spigel

Get full text

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer by Wei Guo, Manish R Patel, Nashat Gabrail, Jordi Rodon, Erika Hamilton, Timothy A Yap, Meghan Duncan, Alberto Bessudo, Jasgit Sachdev, Lena Evilevitch, Sujatha Kumar, Sharon Lu, Bruce J Dezube

Get full text

640 The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients with metastatic breast cancer by Gady Cojocaru, Inbal Barbiro, Manish Patel, Manish Sharma, Dale Shepard, Drew Rasco, Bartosz Chmielowski, Kyriakos P Papadopoulos, Eran Ophir, Ecaterina Dumbrava, Erika Hamilton, Pierre Ferre, Daniel Vaena, Judy S Wang, Adeboye H Adewoye

First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer by Lini Pandite, Simon Metenou, Debra L Richardson, Erika Hamilton, Linda Van Le, Bo Ma, Fatima Rangwala, Nehal J Lakhani, Justin Call, Daphne Stewart, Lauren E Dockery, Guanfang Wang, Jade Huguet, Elliot Offman

Get full text

194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial by Victor Moreno, Ignacio Melero, Michael Millward, Tracy Liu, Rafał Stec, Erika Hamilton, Ana Maria Arance, Jennifer S Michaelson, Laura Liu, Alexander I Spira, Judy S Wang, Irina M Shapiro, Kerry A Whalen, Jeffrey A Jones

313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms by Xiaoyu Zhang, Sanjeev Kaul, Paul Moore, Jason Luke, Bartosz Chmielowski, Hedy Kindler, Francine Chen, George Blumenschein, Erika Hamilton, Shakeela Bahadur, Cesar Santa-Maria, Janine Koucheki, Jichao Sun, John Muth, Patrick Kaminker, Bradley Sumrow

741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced s... by Omid Hamid, Siqing Fu, Manish Sharma, Anna Spreafico, Kyriakos P Papadopoulos, Erika Hamilton, Alexander Spira, Quincy Chu, Brigette Ma, Emily Roberts-Thomson, Dih-Yih Chen, Judy S Wang, Scott A Laurie, Mark R Bray, Roger Sidhu

Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activa... by Erika Hamilton, Dejan Juric, Nora Zizlsperger, Hatem Soliman, Charley Hubbard, Anthony Elias, Brenda C O'Connell, Donna Fitzgerald, Jeffrey L Kutok, Judith Varner, Robert Ilaria, Melody A Cobleigh, Kate H R Tkaczuk, Arielle Lee, Shaker Dakhil, Stephane Peluso

Get full text

608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors by Igor Puzanov, Shivaani Kummar, Sylvie Rottey, Patricia LoRusso, Kyriakos P Papadopoulos, Erika Hamilton, Josef Rüschoff, Fiona C Thistlethwaite, Nuria Kotecki, Christopher T Chen, Yvan LeBruchec, Jerzy Dyczkowski, Sara Samari, Marie Toukam, Joseph Boni, Karin Havenith, Serafino Pantano

754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small c... by Haven Garber, Saranya Chumsri, Yazan Migdady, Chul Kim, Erika Hamilton, Jennifer Specht, Babar Bashir, Hirva Mamdani, Heidi Gillenwater, Yeonhee Kim, David R Spigel, Usama Gergis, Hemant S Murthy, Lubna N Chaudhary, Sarah Fitzsimmons, Bishwa J Ganguly, Hajime Hiraragi, Helle Jensen, Mary C Lessig

708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid t... by Jing Wang, Jian Zhang, Jun Zhang, Ning Li, Xiaohua Wu, Elizabeth Lee, Naomi Hunder, Ying Cheng, Debra L Richardson, Erika Hamilton, Lin Wu, Ira Winer, Ian Anderson, Gottfried Konecny, Douglas Orr, Oladapo Yeku, Sandip P Patel, Sharon Ma, Eric Song, Justin A Call, Lian Lu

The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results by Gail D. Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T. Fields, Genee Lee, Donglu Zhang, Peter S. Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M. Violet Lee, Ola Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Hamilton, Patricia LoRusso, Ian Krop, Melissa M. Schutten, Renee Commerford, Mark X. Sliwkowski, Eunpi Cho

Get full text

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection by Andi K. Cani, Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia‐Jen Liu, Jackie Pierce, Kieran Bradbury, Elaine Kilgour, Kimberly Aung, Gaia Schiavon, Danielle Carroll, T. Hedley Carr, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Vicky Rowlands, Elizabeth A. Harrington, J. Carl Barrett, Nitharsan Sathiyayogan, Christopher Morrow, Valeria Sero, Anne C. Armstrong, Richard Baird, Erika Hamilton, Seock‐Ah Im, Komal Jhaveri, Manish R. Patel, Caroline Dive, Scott A. Tomlins, Aaron M. Udager, Daniel F. Hayes, Costanza Paoletti

Get full text